PGDx Response to COVID-19
We continue to monitor the situation closely and will inform our valued partners immediately if there is any change to that. For more information, click the button below.
EMPOWERING THE FIGHT AGAINST CANCER
Cancer is a disease of the genome. In order to understand it, we need to understand the genomic drivers to provide personalized treatments that give patients the best chance at beating their cancer. We are committed to improving clinical insight, speed of results, and health economics through a portfolio of regulated, comprehensive tissue-based and liquid biopsy Next-Generation Sequencing (NGS) products designed to be used and scaled in laboratories and health systems worldwide.
Today, 80% of patients aren’t being tested, or aren’t being tested in the window of time that it actually makes a difference for their treatment decisions.
We are changing that.
Unlock Actionable Information
from the Genome
Personal Genome Diagnostics (PGDx) provides advanced cancer genome analysis to help researchers and partners identify elusive cancer-related genetic changes.
- Sequence Mutations
- Copy Number Alterations
PGDx establishes co-development partnerships to create companion diagnostic products for personalized medicines of the future.
PGDx partners with pharmaceutical companies to help accelerate biomarker driven drug development.
GLOBAL PATIENT ACCESS TO IVD KITS
PGDx offers validated tissue and liquid biopsy kits with an automated bioinformatics pipeline, enabling local NGS testing in laboratories worldwide.
Personal Genome Diagnostics Announces Medicare Coverage of PGDx elio™ tissue complete Assay for Patients with Advanced Cancer
Sep 09, 2020